-
公开(公告)号：EP2895505A1
公开(公告)日：2015-07-22
申请号：EP13765701.1
申请日：2013-09-17
发明人： TOLBORG, Jakob Lind , FOSGERAU, Keld , NØRREGARD, Pia , JUST, Rasmus , RIBER, Ditte , HAMPRECHT, Dieter Wolfgang , AUGUSTIN, Robert , THOMAS, Leo , RIST, Wolfgang
IPC分类号： C07K14/605 , A61K38/26
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供了用于治疗肥胖和过量体重，糖尿病和其他相关代谢紊乱的材料和方法。 特别地，本发明提供了在这些方法中有效的新型胰高血糖素类似物肽。 与人胰高血糖素相比，肽可以通过增加对GLP-1受体的选择性来介导其作用。
-
公开(公告)号：EP3057984B1
公开(公告)日：2018-07-11
申请号：EP14795564.5
申请日：2014-10-17
IPC分类号： C07K14/605 , A61K38/26 , A61K38/28 , A61K45/06 , A61K31/137 , A61K31/155 , A61K31/198 , A61K31/485 , A61K31/7048
CPC分类号： C07K14/605 , A61K31/137 , A61K31/155 , A61K31/198 , A61K31/485 , A61K31/7048 , A61K38/26 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
-
公开(公告)号：EP3283507A1
公开(公告)日：2018-02-21
申请号：EP16717132.1
申请日：2016-04-15
IPC分类号： C07K14/605 , A61K38/26
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
-
公开(公告)号：EP2895505B1
公开(公告)日：2019-11-06
申请号：EP13765701.1
申请日：2013-09-17
发明人： TOLBORG, Jakob Lind , FOSGERAU, Keld , NØRREGARD, Pia , JUST, Rasmus , RIBER, Ditte , HAMPRECHT, Dieter Wolfgang , AUGUSTIN, Robert , THOMAS, Leo , RIST, Wolfgang
IPC分类号： C07K14/605 , A61K38/26
-
-
公开(公告)号：EP3057983A2
公开(公告)日：2016-08-24
申请号：EP14793463.2
申请日：2014-10-17
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供了用于治疗肥胖和过量体重，糖尿病和其他相关代谢紊乱的材料和方法。 特别地，本发明提供了在这些方法中有效的新型胰高血糖素类似物肽。 与人胰高血糖素相比，肽可以通过增加对GLP-1受体的选择性来介导其作用。
-
公开(公告)号：EP2793931A2
公开(公告)日：2014-10-29
申请号：EP12816470.4
申请日：2012-12-19
IPC分类号： A61K38/26 , C07K14/605
CPC分类号： C07K14/605 , A61K38/00 , A61K38/26 , A61K45/06 , A61K2300/00
摘要： The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供胰高血糖素类似物肽及其用于促进体重减轻或预防体重增加，以及治疗肥胖症或过量体重和相关病症的用途。 该化合物也可用于改善血糖控制和/或治疗糖尿病。 这些化合物尤其可以通过与人胰高血糖素相比增加对GLP-1受体的选择性而介导其作用。
-
公开(公告)号：EP3057984A1
公开(公告)日：2016-08-24
申请号：EP14795564.5
申请日：2014-10-17
IPC分类号： C07K14/605 , A61K38/26
CPC分类号： C07K14/605 , A61K31/137 , A61K31/155 , A61K31/198 , A61K31/485 , A61K31/7048 , A61K38/26 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供了用于治疗肥胖和过量体重，糖尿病和其他相关代谢紊乱的材料和方法。 特别地，本发明提供了在这些方法中有效的新型酰化胰高血糖素类似物肽。 与人胰高血糖素相比，肽可以通过增加对GLP-1受体的选择性来介导其作用。
-
公开(公告)号：EP2844670B1
公开(公告)日：2017-12-06
申请号：EP13721953.1
申请日：2013-05-03
申请人： Zealand Pharma A/S
CPC分类号： C07K14/605 , A61K35/22 , A61K35/48 , A61K35/54 , A61K35/63 , A61K35/64 , A61K38/26 , A61K45/06
摘要： GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis, treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
-
10.发明授权
公开(公告)号：EP2525809B1
公开(公告)日：2016-08-03
申请号：EP11704174.9
申请日：2011-01-20
申请人： Zealand Pharma A/S
发明人： PETERSEN, Jørgen Søberg , KJOELBYE, Anne Louise , SKOVGAARD, Marie , PEDERSEN, Henrik Duelund , AXELSEN, Lene , RIBER, Ditte , MEIER, Eddi , HANSEN, Rie Schultz , FOSGERAU, Keld , LARSEN, Bjarne Due
CPC分类号： C07K14/605 , A61K38/26 , C07K14/4705
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.021 秒)
